Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | LOX | P28300 | 2/20 | 0.42 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.42 |
| ▸ | LOXL4 | Q96JB6 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28585189 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1MAPTMEN1GAA | |
| SCHEMBL18770503 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1MAPTMEN1GAA | |
| SCHEMBL17290426 | 0.79 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1MAPTMEN1GAA | |
| SCHEMBL420793 | 0.77 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1MAPTMEN1GAA | |
| SCHEMBL11047547 | 0.76 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1MAPTMEN1GAA | |
| SCHEMBL17290978 | 0.75 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1MAPTMEN1GAA | |
| SCHEMBL16091682 | 0.75 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1MAPTMEN1GAA | |
| SCHEMBL7253735 | 0.72 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1MAPTMEN1GAA | |
| SCHEMBL18345390 | 0.71 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1MAPTMEN1GAA | |
| SCHEMBL420794 | 0.71 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1MAPTMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128529-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | NOBELPHARMA CO., LTD. (JP) | 2021-05-06 | — | — | US | disclosed |
| CN-112118839-A | Pyrazolone derivative-containing drug | 耐贝医药株式会社 | 2020-12-22 | — | — | CN | disclosed |
| EP-3666270-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | Nobelpharma Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-1793821-B1 | PYRAZOLONE COMPOUNDS FOR TREATING CEREBROVASCULAR DISORDERS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-10004720-B2 | Agent for preventing and/or treating ophthalmologic diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20170273949-A1 | AGENT FOR PREVENTING AND/OR TREATING OPHTHALMOLOGIC DISEASES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-09-28 | — | — | US | disclosed |
| US-9259416-B2 | Pyrazolone compounds useful for treatment of cerebrovascular disorders associated with ischemic stroke | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-02-16 | — | — | US | disclosed |
| US-8183206-B2 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-1437137-B1 | DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-7312239-B2 | Medicament for prevention and/or therapy of arterial wall disorder | MITSUBISHI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20060135588-A1 | Preventive and/or therapeutic drugs for inflammatory intestinal diseases | MITSUBISHI PHARMA CORPORATION (JP) | 2006-06-22 | — | — | US | disclosed |
| US-20060111418-A1 | Blood-brain barrier disruption inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1582517-A1 | BLOOD-BRAIN BARRIER DISRUPTION INHIBITORS | Mitsubishi Pharma Corporation (JP) | 2005-10-05 | — | — | EP | disclosed |
| EP-1553087-A1 | PREVENTIVE AND/OR THERAPEUTIC DRUGS FOR INFLAMMATORY INTESTINAL DISEASES | Mitsubishi Pharma Corporation (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-20050009896-A1 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040254234-A1 | Medicament for prevention and/or therapy of arterial wall disorder | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1437137-A1 | DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE | Mitsubishi Pharma Corporation (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-0208874-B1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR CIRCULATORY DISORDERS | MITSUBISHI KASEI CORPORATION (JP) | 1993-03-24 | — | — | EP | disclosed |
| US-4857542-A | INHIBITOR AGAINST LIPID PEROXIDATION | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0208874-A1 | Prophylactic and therapeutic agent for circulatory disorders | MITSUBISHI KASEI CORPORATION (JP) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273949-A1 | AGENT FOR PREVENTING AND/OR TREATING OPHTHALMOLOGIC DISEASES | MITF, EYA3, AQP1 | SMN1; SMN2 4071/4885ALDH1A1 344/4885MAPT 2342/4885 |
| US-20040254234-A1 | Medicament for prevention and/or therapy of arterial wall disorder | ADRB3, TNNI3, AGTR1 | SMN1; SMN2 4415/4885ALDH1A1 662/4885MAPT 4769/4885 |
| US-20060111418-A1 | Blood-brain barrier disruption inhibitor | FABP7, AQP4, AQP1 | SMN1; SMN2 4680/4885ALDH1A1 320/4885MAPT 2923/4885 |
| US-20050009896-A1 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | PLAT, PTGIS, SERPINC1 | SMN1; SMN2 1422/4885ALDH1A1 288/4885MAPT 4680/4885 |
| US-20210128529-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | CYP11B2, CYP3A5, DPYD | SMN1; SMN2 3003/4885ALDH1A1 285/4885MAPT 4271/4885 |
| US-10004720-B2 | Agent for preventing and/or treating ophthalmologic diseases | MITF, EYA3, AQP1 | SMN1; SMN2 4071/4885ALDH1A1 344/4885MAPT 2342/4885 |
| US-20060135588-A1 | Preventive and/or therapeutic drugs for inflammatory intestinal diseases | SLC10A2, FABP2, AADAC | SMN1; SMN2 4750/4885ALDH1A1 457/4885MAPT 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.